MDxHealth (NASDAQ:MDXH) Posts Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• MDxHealth reported a quarterly loss of ($0.15) earnings per share, which was below analysts' expectations of ($0.13).
• The company has updated its Q2 2025 guidance to a range of -0.150 to -0.150 EPS, indicating consistent losses ahead.
• MDxHealth stock saw a slight increase, trading at $2.49 with a market capitalization of $117.75 million and a negative PE ratio of -2.17.

MDxHealth (NASDAQ:MDXH - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02), Zacks reports. The company had revenue of $26.60 million for the quarter, compared to the consensus estimate of $26.60 million. MDxHealth had a negative return on equity of 274.67% and a negative net margin of 34.98%. MDxHealth updated its Q2 2025 guidance to -0.150--0.150 EPS.

MDxHealth Trading Down 1.5%

Shares of MDXH stock traded down $0.04 on Friday, reaching $2.66. 54,832 shares of the stock were exchanged, compared to its average volume of 97,636. The stock has a market cap of $125.79 million, a PE ratio of -3.02 and a beta of 1.41. MDxHealth has a one year low of $1.35 and a one year high of $3.50. The company has a debt-to-equity ratio of 13.81, a current ratio of 2.00 and a quick ratio of 1.92. The stock has a 50 day moving average price of $2.26 and a 200 day moving average price of $1.92.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MDXH. Craig Hallum began coverage on MDxHealth in a research report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price objective for the company. Wall Street Zen upgraded MDxHealth to a "hold" rating in a research report on Saturday, May 24th.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.